|Systematic (IUPAC) name|
|Legal status||℞ Prescription only|
|Metabolism||converted to spiraprilat|
|Half-life||30 to 35 hours|
|Excretion||Hepatic and renal|
|Mol. mass||466.616 g/mol|
| (what is this?)
Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment. However data on its effect upon the renal function is conflicting.
It is produced synthetically by combining the following two pharmaceutical intermediates:
(S)-1,4-Dithia-7-azaspiro(4,4)-nonane-8-carboxylic acid hydrobromide CAS 75776-79-3
N-[1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-Alanine (ECPPA) 
- Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). "Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.". Scand J Urol Nephrol 33 (1): 57–62. doi:10.1080/003655999750016294. PMID 10100366.
- Noble S, Sorkin E (1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.". Drugs 49 (5): 750–66. PMID 7601014.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|